Lilly Acquires Ventyx Biosciences for $1.2 Billion to Expand Inflammation Treatment Pipeline
Eli Lilly acquires Ventyx Biosciences for $1.2 billion to advance oral therapies targeting chronic inflammation in heart, brain, and autoimmune diseases.
/ 88 items
#NVO↓
Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
Novo Nordisk Slashes Wegovy Prices in China by 50%
Novo Nordisk cuts Wegovy obesity drug prices by half in Chinese provinces as patent expiration looms and local competitors prepare cheaper alternatives.
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Lilly's Oral Weight Loss Pill Maintains Results After Injectables
Eli Lilly's (LLY) orforglipron oral pill successfully maintained weight loss in patients switching from injectable GLP-1 drugs, offering a more convenient obesity treatment option with FDA decision expected early 2026.
Eli Lilly's Groundbreaking Obesity Drug Shows Record-Breaking Weight Loss Results
Eli Lilly's experimental retatrutide helps patients lose up to 24% body weight in trials, setting new standards for obesity treatment but with notable side effects and dropout rates.